Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1804-1813

  Gilg, Anne G ^a   Tye, Sandra L ^a   Tolliver, Lauren B ^a   Wheeler, William G ^a   Visconti, Richard P ^a   Duncan, James D ^a   Kostova, Felina V ^a   Bolds, Letitia N ^b   Toole, Bryan P ^a   Maria, Bernard L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD45 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYALURONIC ACID; NESTIN; PROTEIN KINASE B BETA;

ANIMAL CELL; APOPTOSIS; ARTICLE; BIOLOGICAL THERAPY; CANCER GROWTH; CANCER INVASION; CANCER SIZE; CELL ACTIVATION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENGRAFTMENT; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MULTIPOTENT STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; RAT; SPINAL CORD;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; GLIOMA; HYALURONIC ACID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; POLYMERS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 41549125075     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1228     Document Type: Article

References (46)

1. Fox K, Caterson B. Freeing the brain from the perineuronal net. Science 2002;298:1187-9.
2. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 2000;57:276-89.
3. Deepa SS, Carulli D, Galtrey C, et al. Composition of perineuronal net extracellular matrix in rat brain: a different disaccharide composition for the net-associated proteoglycans. J Biol Chem 2006;281: 17789-800.
4. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004;4:528-39.
5. Delpech B, Maingonnat C, Girard N, et al. Hyaluronan and hyaluronectin in the extracellular matrix of human brain tumour stroma. Eur J Cancer 1993;7: 1012-7.
6. Maleski M, Hockfield S. Glial cells assemble hyaluronan-based pericellular matrices in vitro. Glia 1997; 20:193-202.
7. Ranuncolo SM, Ladeda V, Specterman S, et al. CD44 expression in human gliomas. J Surg Oncol 2002;79: 30-5; discussion 5-6.
8. Bouvier-Labit C, Liprandi A, Monti G, Pellissier JF, Figarella-Branger D. CD44H is expressed by cells of the oligodendrocyte lineage and by oligodendrogliomas in humans. J Neurooncol 2002;60:127-34.
9. Zhou R, Wu X, Skalli O. The hyaluronan receptor RHAMM/IHABP in astrocytoma cells: expression of a tumor-specific variant and association with microtubules. J Neurooncol 2002;59:15-26.
10. Okada H, Yoshida J, Sokabe M, Wakabayashi T, Hagiwara M. Suppression of CD44 expression decreases migration and invasion of human glioma cells. Int J Cancer 1996;66:255-60.
11. Radotra B, McCormick D. Glioma invasion in vitro is mediated by CD44-hyaluronan interactions. J Pathol 1997;181:434-8.
12. Akiyama Y, Jung S, Salhia B, et al. Hyaluronate receptors mediating glioma cell migration and proliferation. J Neurooncol 2001;53:115-27.
13. Koochekpour S, Pilkington GJ, Merzak A. Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro. Int J Cancer 1995;63:450-4.
14. Radotra B, McCormick D. CD44 is involved in migration but not spreading of astrocytoma cells in vitro. Anticancer Res 1997;17:945-9.
15. Ward JA, Huang L, Guo H, Ghatak S, Toole BP. Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells. Am J Pathol 2003;162: 1403-9.
16. Ghatak S, Misra S, Toole BP. Hyaluronan regulates constitutive ErbB2 phosphorylation and signal complex formation in carcinoma cells. J Biol Chem 2005; 280:8875-83.
17. Misra S, Toole BP, Ghatak S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem 2006;281:34936-41.
18. Ghatak S, Misra S, Toole BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 2002;277:38013-20.
19. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998;8: 1195-9.
20. Misra S, Ghatak S, Zoltan-Jones A, Toole BP. Regulation of multi-drug resistance in cancer cells by hyaluronan. J Biol Chem 2003;278:25285-8.
21. Misra S, Ghatak S, Toole BP. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 2005;280:20310-5.
22. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
23. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007;58: 267-84.
24. Piccirillo SGM, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444:761-5.
25. Hill RP, Perris R. "Destemming" cancer stem cells. J Natl Cancer Inst 2007;99:1435-40.
26. Nilsson SK, Haylock DN, Johnston HM, Occhiodoro T, Brown TJ, Simmons PJ. Hyaluronan is synthesized by primitive hemopoietic cells, participates in their lodgment at the endosteum following transplantation, and is involved in the regulation of their proliferation and differentiation in vitro. Blood 2003;101: 856-62.
27. Avigdor A, Goichberg P, Shivtiel S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004;103:2981-9.
28. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005;65:6207-19.
29. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006;312:3701-10.
30. Zeng C, Toole BP, Kinney SD, Kuo JW, Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 1998;77:396-401.
31. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med1996;183:1797-806.
32. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 2004; 101:781-6.
33. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64: 7011-21.
34. Muir D, Johnson J, Rojiani M, Inglis BA, Rojiani A, Maria BL. Assessment of laminin-mediated glioma invasion in vitro and by glioma tumors engrafted within rat spinal cord. J Neurooncol 1996;30:199-211.
35. Mokry J, Cizkova D, Filip S, et al. Nestin expression by newly formed human blood vessels. Stem Cells Dev 2004;13:658-64.
36. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353: 2012-24.
37. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60.
38. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8.
39. Leggas M, Panetta JC, Zhuang Y, et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006;66: 4802-7.
40. Elkind NB, Szentpetery Z, Apati A, et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 2005;65:1770-7.
41. Takada T, Suzuki H, Gotoh Y, Sugiyama Y. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab Dispos 2005;33:905-9.
42. Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 2005;65:7429-35.
43. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 2006;12:2264-71.
44. Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004;104:2084-6.
45. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal-derived factor-1 recruits vascular progenitors tomitotic neovasculature, wheremicroenvironment influences their differentiated phenotypes. Cancer Res 2006;66:9054-64.
46. Luo Y, Cai J, Xue H, Miura T, Rao MS. Functional SDF1 α/CXCR4 signaling in the developing spinal cord. J Neurochem 2005;93:452-62.